What happened

Vivos Therapeutics, Inc. (NASDAQ: VVOS) said cost cuts narrowed its third-quarter operating loss 18% to $3.9 million from $4.7 million a year earlier.

Revenue was $6.4 million, up 24% from $5.2 million in the second quarter. The company exchanged about $6.1 million of senior secured debt for equity during 2026. It regained Nasdaq's stockholders' equity compliance after closing its SOD Sciences transaction on Oct. 16.

For holders, the test is whether lower costs and a repaired equity balance buy enough time for new clinical initiatives to lift revenue.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

Where the cost cuts show up

Third-quarter operating expenses fell 17% to $7.2 million from $8.7 million a year earlier. General and administrative costs dropped $1.4 million, mainly from lower professional fees, equipment maintenance and office expenses. Sales and marketing spending also fell.

Chairman and Chief Executive Officer Kirk Huntsman said those two lines together declined $1.6 million. He said the company has now eliminated an estimated $5 million or more in annual operating costs, with more efficiencies underway.

The sequential revenue gain does not carry over year over year. Revenue in the third quarter of 2025 was $6.8 million. Product revenue fell to $1.8 million from $2.2 million as the company moved away from appliance sales to dentists in its Vivos Integrated Provider (VIP) program. Service revenue edged up 1% to $4.6 million.

Gross margin slipped to 52% from 58% a year earlier, which the company blamed on lower product revenue. Over nine months, service revenue rose 57% to $12.1 million, mainly from sleep testing and resulting treatment services in Nevada. Gross margin was 56% against 55%.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

A profit margin expresses the specified profit measure as a share of sales.

Why it matters

OptimistFi has argued that Vivos must prove operating leverage before its balance sheet forces costly financing. The quarter offers partial proof. Expenses fell while revenue grew from the second quarter, so the picture is mixed.

The longer view is less tidy. The nine-month operating loss widened to $15.3 million from $13.5 million. Operating expenses rose to $24.7 million from $21.1 million on the cost of opening two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada.

The net loss flatters the operating result. Net loss fell from $5.4 million a year earlier, but it included about $2.9 million of other income from reversing a previously recorded Employee Retention Credit liability. That is a one-time, non-operating item, not an operating gain.

Explain the financial terms

A balance sheet shows a company's assets, debts and owners' equity at a point in time.

A fiscal quarter is a three-month period in the company's reporting year.

What the balance sheet shows

Cash and cash equivalents were $0.2 million at Sept. 30, down from $2.0 million at Dec. 31, 2025. Total stockholders' equity was $2.4 million, compared with a $1.5 million deficit at year-end. By OptimistFi's calculation, total liabilities fell $6.0 million to $20.7 million from $26.7 million.

The equity repair came with dilution. Common shares outstanding rose to 33,820,768 from 9,286,609 at Dec. 31, 2025. The company lists dilution from conversion of outstanding preferred stock among its risks.

Nasdaq's Oct. 20 notice is subject to continued monitoring. The company also warns that final accounting for the SOD Sciences transaction, or review by Nasdaq or its auditor, could produce a smaller increase in stockholders' equity than expected.

What's next

The nearest dated test is Nasdaq's minimum bid price requirement. The company lists as a risk that it will not regain compliance by Dec. 2, 2026 or any extended deadline, or that stockholders will not approve a proposed reverse stock split. A closing bid of $0.10 or less for ten consecutive business days would bring a delisting determination with no compliance period.

Management expects new initiatives to add to revenue and margins starting in the fourth quarter of 2026 and more through 2027. They include EEG testing and insomnia treatment, CPAP set-up and remote monitoring, and renegotiated payer contracts.

Higher revenue and margins in the fourth-quarter report would support the case. Another large equity issuance to fund operations would weaken it.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

Sources checked automatically Nov 17, 2026 · Human review: none
Thesis impactVVOS: no published thesis yet.